Physician profile
Gary Trey
NPI 1508853417
$4,753.47
in general payments reported to CMS, 2019-2025
36 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $63.95 · 2021: $421 · 2022: $988 · 2023: $1,113 · 2024: $1,353 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,112 · Education: $51.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,111.83 |
| Education | $51.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,903.69 | 2020-2025 | Linzess, Creon, Viberzi |
| Pfizer INC. | $460.81 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.47 | 2022-2025 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $215.46 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.61 | 2022 | |
| Lilly USA, LLC | $146.63 | 2022-2025 | Mounjaro, Omvoh, Zepbound |
| Janssen Biotech, INC. | $139.71 | 2021-2024 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $123.05 | 2021 | |
| Redhill Biopharma INC. | $118.62 | 2021-2022 | |
| Eisai INC. | $116.94 | 2019 | |
| Qol Medical, LLC | $100.83 | 2023-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $98.72 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $95.23 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $71.45 | 2023-2024 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $63.86 | 2024 | |
| Ucb, INC. | $61.53 | 2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $59.40 | 2023-2024 | Breztri, Airsupra |
| Intercept Pharmaceuticals, INC. | $51.43 | 2025 | |
| Celltrion USA INC. | $51.01 | 2024 | Zymfentra |
| Biohaven Pharmaceuticals, INC. | $49.36 | 2021 | |
| Merck Sharp & Dohme LLC | $35.25 | 2023-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $34.99 | 2025 | Iqirvo |
| Esperion Therapeutics, INC. | $33.61 | 2024 | Nexletol |
| Novo Nordisk INC | $31.72 | 2023-2024 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $25.25 | 2023 | |
| Idorsia Pharmaceuticals US INC | $24.43 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $21.09 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $20.45 | 2025 | Vowst |
| Impel Pharmaceuticals INC. | $19.43 | 2023 | Trudhesa |
| Amgen INC. | $18.79 | 2023 | Amjevita |
| Shield Therapeutics INC | $17.70 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.19 | 2021 | |
| Echosens North America, INC. | $13.73 | 2023 | Fibroscan |
| Braintree Laboratories, INC. | $11.82 | 2021 | |
| Ardelyx, INC. | $11.21 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Trey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.